- Trials with a EudraCT protocol (7)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
7 result(s) found for: Liver regeneration.
Displaying page 1 of 1.
EudraCT Number: 2013-004644-28 | Sponsor Protocol Number: 13-129 | Start Date*: Information not available in EudraCT |
Sponsor Name:RWTH Aachen University, represented by the Rector, himself, represented by the Dean of the Medical Faculty | ||
Full Title: Administration of Rifaximin to improve Liver Regeneration and Outcome following Major Liver Resection | ||
Medical condition: Patients undergoing major liver resection will be included into the study | ||
Disease: | ||
Population Age: Elderly | Gender: Male, Female | |
Trial protocol: DE (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2013-001974-11 | Sponsor Protocol Number: HEPATOTEST | Start Date*: 2013-08-29 |
Sponsor Name:INSTITUTO DE INVESTIGACION SANITARIA LA FE | ||
Full Title: PILOT TRIAL FOR THE EVALUATION OF HEPATOTEST IN PREOPERATIVE ASSESSMENT IN LIVER FUNCTION. | ||
Medical condition: Patients with liver metastases (mainly colorectal cancer) who will be undergoing major hepatic resection (3 or more liver segments) which have been treated with neoadjuvant chemotherapy. | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: ES (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2014-003561-15 | Sponsor Protocol Number: MYSTEP1 | Start Date*: 2016-08-30 | |||||||||||
Sponsor Name:University Hospital of Tuebingen | |||||||||||||
Full Title: Safety and Tolerance of Immunomodulating Therapy with Donor-specific Mesenchymal Stem Cells in Pediatric Living-Donor Liver Transplantation | |||||||||||||
Medical condition: Side effects of life-long immunosuppressive medication account for major morbidity after pediatric liver transplantation and impair quality of life. In-vivo and in-vitro studies have shown that MSC... | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2010-024527-25 | Sponsor Protocol Number: CRAD001H2307 | Start Date*: 2013-07-23 | |||||||||||
Sponsor Name:Novartis Farma SpA | |||||||||||||
Full Title: A 24 month, randomized, controlled, study to evaluate the efficacy and safety of concentration-controlled everolimus plus reduced tacrolimus compared to standard tacrolimus in recipients of living ... | |||||||||||||
Medical condition: Adults with end stage liver disease patients requiring a liver transplant. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-001960-31 | Sponsor Protocol Number: S54348 | Start Date*: 2013-05-03 |
Sponsor Name:UZ Leuven | ||
Full Title: Combined drug Approach to Prevent Ischemia-reperfusion injury during Transplantation of Livers (CAPITL): a first-in-men study | ||
Medical condition: Investigation of the ischemia-reperfusion injury in patients who will undergo a liver transplantation after receiving a drug combination/multifactorial modulation | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: BE (Completed) | ||
Trial results: View results |
EudraCT Number: 2016-003975-23 | Sponsor Protocol Number: IGX1-ENT-XS-16-01 | Start Date*: 2020-04-20 | |||||||||||
Sponsor Name:Asherman Therapy S.L.U. | |||||||||||||
Full Title: Efficacy and safety of autologous, mobilized, non-expanded CD133+ cells to treat Asherman´s Syndrome: A prospective, multi-center, phase I/II clinical trial. | |||||||||||||
Medical condition: Asherman's syndrome also known as intrauterine synechiae | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2010-022235-10 | Sponsor Protocol Number: ITCC-015/EWOG-MDS-Azacytidine-2010 | Start Date*: 2012-03-07 | ||||||||||||||||
Sponsor Name:Erasmus MC | ||||||||||||||||||
Full Title: A Phase I/II study of Azacitidine (Vidaza®) in pediatric patients with relapsed high-grade pediatric MDS or JMML | ||||||||||||||||||
Medical condition: Relapsed advanced Myelodysplastic Syndromes (MDS) and Juvenile Myelomonocytic Leukemia (JMML) | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | |||||||||||||||||
Trial protocol: NL (Completed) CZ (Completed) IT (Prematurely Ended) AT (Prematurely Ended) DE (Prematurely Ended) DK (Prematurely Ended) IE (Prematurely Ended) ES (Prematurely Ended) | ||||||||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
